Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757877 | 0.86 | CHRNB2 (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL16758171 | 0.85 | SIGMAR1 (0.46) | — | |
| SCHEMBL16757828 | 0.81 | DCPS (0.36) | — | |
| SCHEMBL16757792 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL20758197 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL28036941 | 0.81 | SIGMAR1 (0.60) | — | |
| SCHEMBL28037360 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL1391640 | 0.78 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL20758521 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA4 | |
| SCHEMBL28037022 | 0.77 | CHRNB2 (0.58) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074384-B1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-05-22 | — | — | EP | disclosed |
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | disclosed |
| EP-3074384-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GLP1R | CHRNB2 520/4885CHRNA4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.